Suven gets patents for neuro-degenerative drug
The Dollar Business Bureau Suven Life Sciences (Suven) on Tuesday announced it has received approvals of one product patent each from India and South Africa. “One product patent from India and one product patent from South Africa corresponding to the New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases," the company said in an announcement. These two patents are valid through 2028 and 2032 respectively. The granted patents include the class of 5-HT6 compounds and H3 inverse agonist compounds. There are being developed as therapeutic agents and will be used for the treatment of cognitive impairment related to neurodegenerative disorders such as Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, major depressive disorder (MDD), Parkinson and Schizophrenia. With the grants of ...
Suven secures product patents in Israel, Mexico
Suven Life Sciences announced that they have been granted product patent for one product from Israel and for another from Mexico. The grant was corresponding to the new chemical entities which are used for the treatment of disorders related to Neurodegenerative diseases. These patents are valid through 2032. These granted patent claims include the class of selective 5-HT4 compounds. The product is being developed as a therapeutic agent and is used in the treatment of cognitive impairment related to neurodegenerative impairment like Attention deficient hyperactivity disorder (ADHD), Alzheimer’s disease, Schizophrenia, Parkinson’s and Huntington’s disease. With these new grants, Suven has a total of ten granted patents from Israel and 21 granted patent products from Mexico. All these patents are exclusive property of Suven which ...
Suven bags 4 patents in Australia, Eurasia, Israel, US
The Dollar Business Bureau Suven Life Sciences has received patents for its New Chemical Entities (NCEs) in Australia, Eurasia, Israel and USA. The new drug is used in the treatment of cognitive impairment related with neurodegenerative disorders. The patents are valid till 2032, 2030 and 2031 respectively, the company said in a statement on Monday. With these, Suven has around twenty-four granted patents from Australia, seventeen patents from Eurasia, nine from Israel and another twenty-four from USA. These granted patents are intellectual property of the company. They are accomplished through the firm’s internal efforts of the research and development team, it said. The granted patents include the class of selective H3 ligands from Suven which are being developed as therapeutic agents for neurodegenerative ...
Indian firm secures drug patents in five countries
The Dollar Business Bureau Hyderabad-based biopharmaceutical manufacturer Suven Life Sciences Ltd. on Thursday announced that it has secured five product patents in China, Israel, Mexico, Singapore and Sri Lanka. The patents will be used to treat disorders associated with Neurodegenerative diseases. “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven Life Sciences Ltd. Among the granted patents is the class of selective 5-HT compounds, which was discovered by Suven earlier this year. The patents are being developed as therapeutic agents and will be used to treat neurodegenerative ...
